SCHEMBL6499900

SCHEMBL6499900

Cc1ccc(C2=C(C(=O)Nc3ccc(N4CCN(Cc5ccc[nH]5)CC4)cc3)CCCC2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.46
DRD4 P21917 1/20 0.46
DRD3 P35462 1/20 0.46
NPC1 O15118 5/20 0.44
RAB9A P51151 5/20 0.44
GFER P55789 2/20 0.44
MAPT P10636 8/20 0.43
KMT2A Q03164 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
KDM4E B2RXH2 2/20 0.43
MEN1 O00255 2/20 0.43
LMNA P02545 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
MCL1 Q07820 1/20 0.43
MAPK1 P28482 2/20 0.42
TSHR P16473 1/20 0.42
ALDH1A1 P00352 2/20 0.41
CYP2C9 P11712 1/20 0.41
HPGD P15428 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6492808 0.89 HIF1A (0.46) DRD2DRD4DRD3NPC1RAB9A
SCHEMBL6498772 0.85 MAPT (0.58) RAB9AMAPTKMT2ASMN1; SMN2KDM4E
SCHEMBL6502650 0.81 MAPT (0.47) NPC1RAB9AGFERMAPTKMT2A
SCHEMBL6499147 0.80 MAPT (0.46) NPC1RAB9AMAPTKMT2ASMN1; SMN2
SCHEMBL6492454 0.80 MAPT (0.41) NPC1RAB9AGFERMAPTKMT2A
SCHEMBL6504210 0.80 KMT2A (0.45) DRD2DRD4DRD3NPC1RAB9A
SCHEMBL6499989 0.80 NPC1 (0.53) NPC1RAB9AMAPTKMT2ASMN1; SMN2
SCHEMBL6490476 0.79 MEN1 (0.42) NPC1RAB9AGFERMAPTKMT2A
SCHEMBL6491504 0.79 FAAH (0.49) RAB9AMAPTKMT2ASMN1; SMN2KDM4E
SCHEMBL6499289 0.76 SRPK1 (0.51) CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed
EP-1472226-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-03 EP disclosed
WO-2003045921-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 DRD2 2927/4885DRD4 3931/4885DRD3 3423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.